On January 11, 2018, Bartels, Bjoern; Jakob-Roetne, Roland; Limberg, Anja; Neidhart, Werner; Ratni, Hasane; Steiner, Sandra; Reutlinger, Michael published a patent.Recommanded Product: 63931-21-5 The title of the patent was Fused pyrimidine derivatives as γ-secretase inhibitors and their preparation. And the patent contained the following:
The invention relates to compounds of formula I, or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers and/or optical isomers and/or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer’s disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome. Compounds of formula I wherein R1 is Ph, lower alkyl, C3-6 cycloalkyl, etc.; R2is H, halo, lower alkyl, etc.; R3 is 5-membered heteroaryl; R4 is (un)substituted lower alkyl; R5 and R5′ are independently H and lower alkyl; A is CH2 and CH2CH2; X is CH and N; and pharmaceutically active acid addition salts, racemic mixtures, enantiomers, optical isomers and stereoisomers thereof, are claimed. Example compound II was prepared by amination of 2-chloro-7-(4-fluorophenyl)-N,5,5-trimethyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-amine with 3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline. The invention compounds were evaluated for their γ-secretase inhibitory activity. From the assay, it was determined that compound II exhibited EC50 value of 5 nM. The experimental process involved the reaction of 5-Bromo-2,4,6-trichloropyrimidine(cas: 63931-21-5).Recommanded Product: 63931-21-5
The Article related to pyrimidine preparation gamma secretase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 63931-21-5
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia